AUB ScholarWorks

Management of paclitaxel-induced hand-foot syndrome

Show simple item record

dc.contributor.author Assi H.A.
dc.contributor.author Ayoub Z.A.
dc.contributor.author Jaber S.M.
dc.contributor.author Sibai H.A.
dc.contributor.author El Saghir N.S.
dc.contributor.editor
dc.date 2013
dc.date.accessioned 2017-10-05T15:43:29Z
dc.date.available 2017-10-05T15:43:29Z
dc.date.issued 2013
dc.identifier 10.1159/000352097
dc.identifier.isbn
dc.identifier.issn 16613791
dc.identifier.uri http://hdl.handle.net/10938/18485
dc.description.abstract Background: Hand-foot syndrome (HFS), also known as acral erythema or palmoplantar dysesthesia, is a manifestation of painful erythema and dysesthesia mostly occurring in the palms and soles. Although many chemotherapeutic agents have been shown to cause HFS, it remains an uncommon adverse cutaneous manifestation of paclitaxel. Case Report: We report a case of paclitaxel-induced grade 3 HFS in a patient with breast cancer. HFS developed after 6 weeks of paclitaxel weekly infusions. The patient was managed by avoidance of sun exposure and extensive use of sunscreen and moisturizers. The skin lesions stabilized and improved gradually. This allowed us to continue the planned necessary course of 12 weeks of paclitaxel under close surveillance. Conclusion: Paclitaxel-induced HFS can be managed with topical creams and avoidance of sun exposure without the need to discontinue chemotherapy. However, close monitoring for any increase or change in symptoms is warranted. © 2013 S. Karger GmbH, Freiburg.
dc.format.extent
dc.format.extent Pages: (215-217)
dc.language English
dc.publisher BASEL
dc.relation.ispartof Publication Name: Breast Care; Publication Year: 2013; Volume: 8; no. 3; Pages: (215-217);
dc.relation.ispartofseries
dc.relation.uri
dc.source Scopus
dc.subject.other
dc.title Management of paclitaxel-induced hand-foot syndrome
dc.type Article
dc.contributor.affiliation Assi, H.A., Department of Internal Medicine, American University of Beirut Medical Center, NK Basile Cancer Institute, P.O. Box: 11-0236, Riad El Solh 1107 2020, Beirut, Lebanon
dc.contributor.affiliation Ayoub, Z.A., Department of Internal Medicine, American University of Beirut Medical Center, NK Basile Cancer Institute, P.O. Box: 11-0236, Riad El Solh 1107 2020, Beirut, Lebanon
dc.contributor.affiliation Jaber, S.M., Department of Internal Medicine, American University of Beirut Medical Center, NK Basile Cancer Institute, P.O. Box: 11-0236, Riad El Solh 1107 2020, Beirut, Lebanon
dc.contributor.affiliation Sibai, H.A., Department of Internal Medicine, American University of Beirut Medical Center, NK Basile Cancer Institute, P.O. Box: 11-0236, Riad El Solh 1107 2020, Beirut, Lebanon
dc.contributor.affiliation El Saghir, N.S., Department of Internal Medicine, American University of Beirut Medical Center, NK Basile Cancer Institute, P.O. Box: 11-0236, Riad El Solh 1107 2020, Beirut, Lebanon
dc.contributor.authorAddress El Saghir, N.S.; Department of Internal Medicine, American University of Beirut Medical Center, NK Basile Cancer Institute, P.O. Box: 11-0236, Riad El Solh 1107 2020, Beirut, Lebanon; email: nagi.saghir@aub.edu.lb
dc.contributor.authorCorporate University: American University of Beirut Medical Center; Faculty: Faculty of Medicine; Department: Naef K. Basile Cancer Institute (NKBCI);
dc.contributor.authorDepartment Naef K. Basile Cancer Institute (NKBCI)
dc.contributor.authorDivision
dc.contributor.authorEmail nagi.saghir@aub.edu.lb
dc.contributor.faculty Faculty of Medicine
dc.contributor.authorInitials Assi, HA
dc.contributor.authorInitials Ayoub, ZA
dc.contributor.authorInitials Jaber, SM
dc.contributor.authorInitials Sibai, HA
dc.contributor.authorInitials El Saghir, NS
dc.contributor.authorOrcidID
dc.contributor.authorReprintAddress El Saghir, NS (reprint author), Amer Univ Beirut, Med Ctr, NK Basile Canc Inst, Breast Ctr Excellence, POB 11-0236, Beirut 11072020, Lebanon.
dc.contributor.authorResearcherID
dc.contributor.authorUniversity American University of Beirut Medical Center
dc.description.cited Cohen PR, 2009, J DRUGS DERMATOL, V8, P61; Cruz A, 2011, ACTA DERM-VENEREOL, V91, P86, DOI 10.2340-00015555-0956; deArgila D, 1996, DERMATOLOGY, V192, P377; Degen A, 2010, J DTSCH DERMATOL GES, V8, P652, DOI 10.1111-j.1610-0387.2010.07449.x; Farhat MH, 2008, ANN SAUDI MED, V28, P374; Hueso L, 2008, Actas Dermosifiliogr, V99, P281; Martin M, 2008, J NATL CANCER I, V100, P805, DOI 10.1093-jnci-djn151; Nagore E, 2000, Am J Clin Dermatol, V1, P225, DOI 10.2165-00128071-200001040-00004; Payne JY, 1996, SOUTHERN MED J, V89, P542, DOI 10.1097-00007611-199605000-00022; Farr Katherina Podlekareva, 2011, Case Rep Oncol, V4, P229, DOI 10.1159-000327767; ROWINSKY EK, 1990, J NATL CANCER I, V82, P1247, DOI 10.1093-jnci-82.15.1247; Susser WS, 1999, J AM ACAD DERMATOL, V40, P367, DOI 10.1016-S0190-9622(99)70488-3; Webster-Gandy JD, 2007, EUR J ONCOL NURS, V11, P238, DOI 10.1016-j.ejon.2006.10.004
dc.description.citedCount 1
dc.description.citedTotWOSCount 1
dc.description.citedWOSCount 1
dc.format.extentCount 3
dc.identifier.articleNo
dc.identifier.coden
dc.identifier.pubmedID
dc.identifier.scopusID 84880735587
dc.identifier.url
dc.publisher.address ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
dc.relation.ispartofConference
dc.relation.ispartofConferenceCode
dc.relation.ispartofConferenceDate
dc.relation.ispartofConferenceHosting
dc.relation.ispartofConferenceLoc
dc.relation.ispartofConferenceSponsor
dc.relation.ispartofConferenceTitle
dc.relation.ispartofFundingAgency
dc.relation.ispartOfISOAbbr Breast Care
dc.relation.ispartOfIssue 3
dc.relation.ispartOfPart
dc.relation.ispartofPubTitle Breast Care
dc.relation.ispartofPubTitleAbbr Breast Care
dc.relation.ispartOfSpecialIssue
dc.relation.ispartOfSuppl
dc.relation.ispartOfVolume 8
dc.source.ID WOS:000321806400009
dc.type.publication Journal
dc.subject.otherAuthKeyword Breast cancer
dc.subject.otherAuthKeyword Hand-foot syndrome
dc.subject.otherAuthKeyword Paclitaxel
dc.subject.otherChemCAS cyclophosphamide, 50-18-0
dc.subject.otherChemCAS epirubicin, 56390-09-1, 56420-45-2
dc.subject.otherChemCAS fluorouracil, 51-21-8
dc.subject.otherChemCAS paclitaxel, 33069-62-4
dc.subject.otherIndex cyclophosphamide
dc.subject.otherIndex epirubicin
dc.subject.otherIndex fluorouracil
dc.subject.otherIndex paclitaxel
dc.subject.otherIndex sunscreen
dc.subject.otherIndex adjuvant chemotherapy
dc.subject.otherIndex aged
dc.subject.otherIndex article
dc.subject.otherIndex axillary lymph node
dc.subject.otherIndex breast cancer
dc.subject.otherIndex case report
dc.subject.otherIndex daily life activity
dc.subject.otherIndex disease surveillance
dc.subject.otherIndex dissection
dc.subject.otherIndex dysesthesia
dc.subject.otherIndex female
dc.subject.otherIndex hand foot syndrome
dc.subject.otherIndex human
dc.subject.otherIndex lymph node dissection
dc.subject.otherIndex partial mastectomy
dc.subject.otherIndex priority journal
dc.subject.otherIndex skin abrasion
dc.subject.otherIndex skin defect
dc.subject.otherIndex skin manifestation
dc.subject.otherIndex skin pigmentation
dc.subject.otherIndex skin tingling
dc.subject.otherIndex skin ulcer
dc.subject.otherIndex sun exposure
dc.subject.otherIndex swelling
dc.subject.otherIndex treatment duration
dc.subject.otherKeywordPlus ACRAL ERYTHEMA
dc.subject.otherKeywordPlus CANCER
dc.subject.otherKeywordPlus TAXOL
dc.subject.otherWOS Oncology
dc.subject.otherWOS Obstetrics and Gynecology


Files in this item

Files Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record

Search AUB ScholarWorks


Browse

My Account